Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
General23 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General24 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
Noosa News22 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News22 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years